Yao Weiqi, Li Boran, Jiang Yingan, Yuan Qiaoyu, Wu Wenjie, Hou Ruizhen, Qi Qi, Dong Haibo, Zhang Yun, Zhang Yu
Wuhan Optics Valley Vcanbio Cell & Gene Technology Co., Ltd., Wuhan, Hubei, China.
Wuhan Optics Valley Vcanbiopharma Co. Ltd., Wuhan, Hubei, China.
Front Immunol. 2025 Jul 4;16:1594373. doi: 10.3389/fimmu.2025.1594373. eCollection 2025.
The therapeutic options for patients with coronavirus disease (COVID-19) are limited. Mesenchymal stem cells (MSCs) have immunomodulatory and regenerative properties that may inhibit excessive inflammatory responses, promote recovery from COVID-19-induced lung injury, and potentially serve as a therapeutic option.
An evaluation of the safety and efficacy of using human umbilical cord mesenchymal stem cells (hUC-MSCs) in 5 critically ill patients with COVID-19 was conducted in this study. In all patients, hUC-MSCs were administered intravenously three times at a dosage of 3 × 10 cells per time, 2 days between each infusion. Safety was evaluated using adverse events. The efficacy was assessed by coagulation function (serum D dimer), inflammatory index (CRP and IL-6) and immune index (lymphocyte count, neutrophil count, CD4, CD19, and CD16 + 56), as well as chest computed tomography (CT) images. Post-infusion visits focused on oxygen saturation and progression of lung lesions.
Infusions of hUC-MSCs were not associated with any serious adverse events. The CT scans indicate that lung lesions have been adequately controlled after receiving the hUC-MSCs. HUC-MSCs injection improved immune system function and alleviated inflammation.
According to our findings, intravenous infusion of hUC-MSCs has proven to be safe, and it has also proven to show potential therapeutic benefits for patients with severe COVID-19.
冠状病毒病（COVID-19）患者的治疗选择有限。间充质干细胞（MSCs）具有免疫调节和再生特性，可能抑制过度炎症反应，促进COVID-19所致肺损伤的恢复，并有可能成为一种治疗选择。
本研究对5例重症COVID-19患者使用人脐带间充质干细胞（hUC-MSCs）的安全性和有效性进行了评估。所有患者均静脉输注hUC-MSCs，每次剂量为3×10⁶细胞，共输注3次，每次输注间隔2天。通过不良事件评估安全性。通过凝血功能（血清D-二聚体）、炎症指标（CRP和IL-6）、免疫指标（淋巴细胞计数、中性粒细胞计数、CD4、CD19和CD16+56）以及胸部计算机断层扫描（CT）图像评估疗效。输注后随访重点关注血氧饱和度和肺部病变进展。
输注hUC-MSCs未发生任何严重不良事件。CT扫描显示，接受hUC-MSCs治疗后肺部病变得到有效控制。hUC-MSCs注射改善了免疫系统功能并减轻了炎症。
根据我们的研究结果，静脉输注hUC-MSCs已被证明是安全的，并且对重症COVID-19患者也显示出潜在的治疗益处。
